Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies
作者： Li-Xin Qiu , Chen Mao , Jian Zhang , Xiao-Dong Zhu , Ru-Yan Liao
DOI: 10.1016/J.EJCA.2010.05.022
关键词: Oncology 、 Cetuximab 、 Cancer 、 Colorectal cancer 、 Metastasis 、 Meta-analysis 、 KRAS 、 Surgery 、 Confidence interval 、 Internal medicine 、 Medicine 、 Monoclonal
摘要: The published data on the predictive and prognostic value of KRAS mutations in metastatic colorectal cancer (mCRC) treated with cetuximab seemed inconclusive. To derive a more …
elsevier.com
sci-hub.se 参考文章(34)
C. Bokemeyer, I. Bondarenko, J. T. Hartmann, F. G. De Braud, C. Volovat, J. Nippgen, C. Stroh, I. Celik, P. Koralewski, KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience Journal of Clinical Oncology. ,vol. 26, pp. 4000- 4000 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.4000
Anthony Gonçalves, Séverine Esteyries, Brynn Taylor-Smedra, Arnaud Lagarde, Mounay Ayadi, Geneviève Monges, François Bertucci, Benjamin Esterni, Jean-Robert Delpero, Olivier Turrini, Bernard Lelong, Patrice Viens, Jean-Paul Borg, Daniel Birnbaum, Sylviane Olschwang, Frédéric Viret, A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer. ,vol. 8, pp. 169- 169 ,(2008) , 10.1186/1471-2407-8-169
F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685
J Baselga, The EGFR as a target for anticancer therapy--focus on cetuximab. European Journal of Cancer. ,vol. 37, pp. 16- 22 ,(2001) , 10.1016/S0959-8049(01)00233-7
Hans Prenen, Jef De Schutter, Bart Jacobs, Wendy De Roock, Bart Biesmans, Bart Claes, Diether Lambrechts, Eric Van Cutsem, Sabine Tejpar, PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clinical Cancer Research. ,vol. 15, pp. 3184- 3188 ,(2009) , 10.1158/1078-0432.CCR-08-2961
Ludovic Barault, Nicolas Veyrie, Valerie Jooste, Delphine Lecorre, Caroline Chapusot, Jean-Marc Ferraz, Astrid Lièvre, Marion Cortet, Anne-Marie Bouvier, Patrick Rat, Patrick Roignot, Jean Faivre, Pierre Laurent-Puig, Francoise Piard, Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers International Journal of Cancer. ,vol. 122, pp. 2255- 2259 ,(2008) , 10.1002/IJC.23388
Deborah Schrag, The price tag on progress--chemotherapy for colorectal cancer. The New England Journal of Medicine. ,vol. 351, pp. 317- 319 ,(2004) , 10.1056/NEJMP048143
Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, Jerzy Zaluski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D'Haens, Tamás Pintér, Robert Lim, György Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine. ,vol. 360, pp. 1408- 1417 ,(2009) , 10.1056/NEJMOA0805019
Fotios Loupakis, Luca Pollina, Irene Stasi, Annamaria Ruzzo, Mario Scartozzi, Daniele Santini, Gianluca Masi, Francesco Graziano, Chiara Cremolini, Eliana Rulli, Emanuele Canestrari, Niccola Funel, Gaia Schiavon, Iacopo Petrini, Mauro Magnani, Giuseppe Tonini, Daniela Campani, Irene Floriani, Stefano Cascinu, Alfredo Falcone, PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 27, pp. 2622- 2629 ,(2009) , 10.1200/JCO.2008.20.2796
W. De Roock, H. Piessevaux, J. De Schutter, M. Janssens, G. De Hertogh, N. Personeni, B. Biesmans, J.-L. Van Laethem, M. Peeters, Y. Humblet, E. Van Cutsem, S. Tejpar, KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Annals of Oncology. ,vol. 19, pp. 508- 515 ,(2008) , 10.1093/ANNONC/MDM496